Uses of Immunosuppression Therapy in Patients With Liver Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01834690|
Recruitment Status : Completed
First Posted : April 18, 2013
Last Update Posted : February 18, 2015
|Condition or disease|
|Evidence of Liver Transplantation|
Specific aims are proposed to achieve in this study:
- To compare graft and patient survival rate, incidence of treatment-related adverse effects between different patterns of immunosuppression combination among patients received post-liver transplant care in Kaohsiung Chang Gung Memorial Hospital (KCGMH), Taiwan.
- To quantify the long-term health impacts of immunosuppressive regimens on quality-adjusted life expectancy (QALE), the loss-of-QALE relating to immunosuppression therapy, and types of transplantation.
|Study Type :||Observational|
|Actual Enrollment :||314 participants|
|Official Title:||Trends of Immunosuppression Therapy and Their Effectiveness in Patients With Liver Transplantation|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
liver transplantation recipients
adult liver transplantation recipients (>=20 years at the date of surgery)
- incidence of graft and patient mortality, treatment-related complications [ Time Frame: 5 years ]Patient will be followed from the date of liver transplantation to the occurence of outcome event for 5 years
- health-related quality of life [ Time Frame: 5 years ]health-related quality of life will be measured by EQ-5D-5L and 15D
- quality-adjusted life expectancy (QALE), loss-of-QALE [ Time Frame: 5 years ]
QALE:quality-adjusted weight for each health status (measured by EQ-5D)will be multiplied by the survival time and then summed to calculate the number of QALE.
Loss-of QALE: the life time expectancy (survival function) for thes study cohort will be compared with Taiwan general population of subjects who are age- and gender-matched with study subjects.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01834690
|Kaohsiung Chang Gung Memorial Hospital|
|Kaohsiung, Taiwan, 833|
|Principal Investigator:||Chien-Ning Hsu, PhD||Chang Gung Memorial Hospital|